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Staphylococcus aureus (S. aureus), a major human pathogen, is
capable of causing many infectious diseases (e.g., pneumonia,
endocarditis, and bacteremia)1. Treatment of methicillin-resistant
S. aureus (MRSA) infections has become challenging because
this pathogen has developed resistance to almost all the standard
of care (SOC) antibiotics2,3. Therefore, there is an urgent need to
develop novel therapeutic strategies against these MRSA life-
threatening infections.
SarA, a key global regulator, binds on target promoters to
control many virulence factors expression in S. aureus4e7. As
reported from prior studies, laboratory-derived sarA mutants
exhibited diminished virulence in animal infection models8,9.
Importantly, we have recently reported that sarA mutants become
methicillin susceptible with significantly reduced oxacillin resis-
tance vs. their respective parental MRSA strains both in vitro and
in experimental endocarditis model10. Therefore, our current
studies focus on antimicrobial agents, which could inhibit sarA
activity, in combination with SOC anti-S. aureus b-lactams in
order to improve and/or repurpose the treatment efficacy of the
antibiotics in MRSA invasive infections.
Hypericin (HYP) is a phenanthropeylene quinine pigment
naturally occurring in Hypericum perforatum L. (commonly known
as St. John’s wort). Preclinical and clinical studies demonstrated
that it possesses a variety of therapeutic activity (e.g., antidepres-
sant11, anticancer12, and antiviral13). In addition, its antimicrobial
properties have also been reported previously, especially on Gram-
positive bacteria (e.g., S. aureus and Listeria monocytogenes)14e17.
However, little is known about its mechanism(s) of action.
In the current studies, we investigated the effect of HYP on the
susceptibility of b-lactam antibiotics (e.g., oxacillin [OXA],
cefazolin [CFZ] and nafcillin [NAF]) and efficacy of HYP in
combination with OXA in a murine bacteremia model due to
MRSA. We demonstrated that HYP significantly decreased the
minimum inhibitory concentrations (MICs) of b-lactam antibi-
otics, biofilm formation and fibronectin binding in parallel with
significantly reduced sarA, agr RNAIII and virulence related genes
expression (e.g., mecA, fnbA and hla) in MRSA. Importantly, HYP
significantly enhanced the efficacy of OXA in an experimental
MRSA bacteremia model. These results suggest that the inhibition
effect of HYP on sarA expression might be responsible for the
synergistic effect with OXA both in vitro and in the treatment
outcome in the MRSA bacteremia model.
2. Materials and methods
2.1. Bacterial strains and growth medium
JE2 strain, a plasmid-cured derivative of LAC MRSA USA300,
was obtained from the National Institutes of Health Network onAntimicrobial Resistance in S. aureus (NARSA)18. A sarA dele-
tion in MRSA strain JE2 was achieved by transducing sarA::kan
mutation from ALC254319. JE2 DmecA is a transposon mutant
with insertion in S. aureus USA 300_0032 and obtained from the
Nebraska Transposon Mutant Library (NTML, Omaha, NE,
USA)10. JE2 DsarA/pmecA is a sarA mutant strain complemented
with pALC6185, which carries the entire mecA locus10. pALC
6185 is a plasmid pEPSA5 containing a 2-kb DNA fragment
containing the mecA coding region20. The study strains were
stored at 80 C until thawed for use. Bacteria were routinely
grown in tryptic soy broth (TSB) or TSB agar plates otherwise
unless specified. All bacterial culture media were purchased from
Becton Dickinson (Franklin Lakes, NJ, USA).
2.2. Determination of MICs
The MICs of HYP (Meilun Biotech, Dalian, China) and b-lactam
antibiotics, including OXA, CFZ, NAF, and other SOC antibiotics
on the study MRSA strains, were determined by a standard broth
microdilution method21 as recommended by the Clinical and
Laboratory Standards Institute (CLSI; Wayne, PA, USA). All the
assays were conducted at least three times on different days and
the most consistent results were presented.
2.3. Checkerboard assay
Checkerboard assays were employed to determine in vitro in-
teractions of HYP and b-lactam antibiotics on the study MRSA
strain JE2 according to the CLSI guidelines22. In brief, a final
inoculum of 5  105 colony-forming unit/mL (CFU/mL) of
MRSA cells was added into 96-well plates containing two-fold
diluted HYP and b-lactam antibiotics in cation-adjusted Mueller
Hinton (CAMH) broth (þ2% NaCl for OXA). After incubation at
37 C for 24 h, the combinational activity of HYP with b-lactam
antibiotic was analyzed by FIC index21. The FIC was interpreted
as follows: synergism, FIC  0.5; antagonism, FIC > 4.0; and
indifferent when 0.5 < FIC  423.
2.4. In vitro time-kill curves
Time-killing experiments were performed using CAMH broth
(þ2% NaCl for OXA) with an initial inoculum of
w5  105 CFU/mL of MRSA cells in the presence of sub-MICs
of b-lactam antibiotics (e.g., 1/4 MIC of OXA, CEF, and NAF)
or HYP (at 1/16  MIC or 1/8  MIC) alone and in combina-
tion21. The concentrations of HYP and antibiotics were chosen
based on the checkerboard assay results. Viability counts were
performed at 0, 2, 4, 6, 8, 12 and 24 h of incubation at 37 C.
Synergistic effect was defined as a 2lg decrease of CFU/mL in
combination vs. the most active drug alone at 24 h of
incubation24.
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Biofilm formation of the study strains was performed as previ-
ously described25,26. Briefly, MRSA cells from fresh culture plates
were washed and adjusted to a density of 0.5 McFarland standard
and diluted 1:10 into brain heart infusion broth supplemented with
0.5% glucose. This suspension was transferred to 96-well tissue
culture plates with study compound alone and in combination
(1/16  MIC or 1/8  MIC of HYP; 1/256  MIC of OXA, CEF,
and NAF) exposure and incubated for 18 h at 37 C. The specific
concentrations of OXA and HYP were chosen based on the impact
of the antibiotic alone on the biofilm formation (See Supporting
Information Tables S1 and S2). After incubation, the wells were
washed, air dried, and stained with safranin (0.1% in distilled
water). The adhering dye was dissolved in 30% acetic acid, and
absorption was measured at OD490nm to quantify biofilm
formation5,26.
2.6. Adherence to fibronectin
Fibronectin adherence assay was performed as previously
described5. Briefly, 6-well tissue culture plates were coated with
purified human fibronectin (50 mg/L, Sigma Chemicals, St. Louis,
USA) for overnight at 4 C and then treated with 3% bovine serum
albumin (Sigma Chemicals) for 3 h at 37 C to prevent nonspecific
adhesion. Overnight cultured MRSA cells with/without HYP
(1/16  MIC or 1/8  MIC), OXA (1/256  MIC) alone and in
combination were adjusted to OD600 nm Z 1.0 (w10
9 CFU/mL)
and subsequently diluted 1:100 into fresh TSB with the same
exposures of the compounds as for the overnight culture and
incubated at 37 C to OD600 nm z 0.5. Then the MRSA cells
(w103 CFU/well) were added into the plates and incubated for
1 h. After 1 h incubation, plates were washed with PBS, TSB agar
was added into each well, and incubated overnight at 37 C.
Adherence to fibronectin was expressed as the percentage
(standard deviation [SD]) of the initial inoculum bound as pre-
viously described27.
2.7. Transcription analyses by quantitative real-time PCR (qRT-
PCR)
Exponential phase of MRSA cells with/without HYP and/or OXA
exposure as descripted in Section 2.6 above were used for theTable 1 Primers used in this study.
Primer Sequence
sarA Forward: 50-TCTTGTTAATG
Reverse: 50-TGTTTGCTTCA
fnbA Forward: 50-CGACACAACC
Reverse: 50-CGTGGCTTACT
mecA Forward: 50-TCCAGATTACA
Reverse: 50-CCACTTCATAT
RNAIII Forward: 50-AATTAGCAAG
Reverse: 50-GATGTTGTTTA
hla Forward: 50-ACAATTTTAGA
Reverse: 50-TCCCCAATTTT
gyrB Forward: 50-CGCAGGCGAT
Reverse: 50-GCTTTCGCTAG
mecA promoter Forward: 50-ATATCGTGAGC
Reverse: 50-TATATACCAAAisolation of total RNA by using a RNeasy kit (Qiagen, Los
Angeles, CA, USA) as described previously10. Briefly, 2 mg of
DNase treated RNA was transcribed into complementary DNA.
The amplification of sarA, agr RNAIII, mecA, fnbA, hla and gyrB
were performed using primers as described previously (see
Table 1)7,28,29. qRT-PCR was performed using an ABI Prism 7000
instrument (Applied Biosystems, Los Angeles, CA, USA) and
SYBR green PCR master kit (Applied Biosystems). gyrB was used
as a control to normalize for transcript quantification. Relative
quantification was calculated by the DDCT method.
2.8. Determination the impact of HYP on SarA-mecA binding by
a gel shift assay
Gel shift assay was performed to determine if SarA regulates
mecA expression by directly binding to the mecA promoter, as
sarA mutants exhibited increased OXA susceptibility vs. their
respective isogenic MRSA parental strain10. Purified SarA protein
was kindly provided by Dr. Ambrose Cheung at Dartmouth
Medical School (Hanover, New Hampshire, USA)30. A 200 bp
fragment encompassing the mecA promoter was generated by PCR
amplification of JE2 DNA using the primer as listed in Table 131.
Then, the mecA promoter DNA was incubated at room tempera-
ture for 20 min with various amounts of purified SarA protein
(e.g., 0.3, 0.6 and 1.2 mg/L) in binding buffer30. To determination
the impact of HYP on Sar-mecA binding, the mecA promoter DNA
and 1.2 mg/L purified SarA protein were incubated at room
temperature for 20 min with various concentrations of HYP (e.g.,
4 and 8 mg/L) in binding buffer. The reaction mixtures were
analyzed in a 6% Tris-Glycine gel (Novex, San Diego, CA, USA).
The band shifts were stained by SYBR Green Electrophoretic
Mobility-Shift Assay (EMSA) Kit (Panomics, Fermont, CA, USA)
and detected by exposing to UV302 nm following the manufac-
turer’s instructions.
2.9. Cell cytotoxicity assay
Cell cytotoxicity was tested by the cell counting kit-8 (CCK-8)
assay, as we previously reported32,33. Briefly, human embryonic
kidney 293 (HEK-293) cells were plated in a 96-well plate. After
overnight incubation, different concentrations of HYP were added.
After 24 h of incubation, the cells were treated with CCK-8 assay
reagent, and OD at 450 nm was measured.Purpose
CACAACAACGTAA-30 RT-PCR
GTGATTCGTTT-30
TCAAGACAATAGCGG-30 RT-PCR
TTCTGATGCCGTTC-30
ACTTCACCAGG-30 RT-PCR
CTTGTAACG-30
TGAGTAACATTTGCTAGT-30 RT-PCR
CGATAGCTTACATGC-30
GAGCCCAACTGAT-30 RT-PCR
GATTCACCAT-30
TTTACCATTA-30 RT-PCR
ATCAAAGTCG-30
AATGAAC TG-30 Gel shift
CCCGACAAC-30
Table 3 MICs and FIC index of OXA in the presence of
HYP against MRSA JE2 wild-type, its isogenic sarA, mecA
mutants and the sarA mutant complemented with mecA strains.
Strain MIC (mg/L) FIC
index
HYP OXA OXAþ1/8 
MIC HYP
JE2 wild-type 64 256 8 0.16
DsarA in JE2 32 4 2 0.56
DmecA in JE2 64 0.5 0.25 0.63
DsarA/pmecA in JE2 64 128 64 0.56
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To further define the effect of HYP on OXA susceptibility against
MRSA in vivo, a well-characterized murine bacteremia model was
used34. All the animal studies complied with the ARRIVE
guidelines35 and the Institutional Animal Care and Use Committee
of Los Angeles Biomedical Research Institute at Harbor-UCLA
Medical Center (Los Angeles, CA, USA) approved the animal
study protocol. CD1 male mice (w6 weeks) were infected by
using exponential phase of MRSA JE2 cells via tail vein
(108 CFU/mouse). At 24 h post-infection, animals were random-
ized into one of the following groups: control (without treatment);
HYP alone at 5 mg/kg, iv, once daily; OXA alone at 100 mg/kg,
im, three times a day (tid); or HYP-OXA combination at the doses
listed above. The HYP dose was selected according to previously
reported regimen in murine model36. The treatment strategy of
OXA encompassed dose-regimens used in prior studies in murine
sepsis model37. Treatment lasted for 3 days. The control animals
were euthanized at 24 h post-infection in order to determine the
MRSA density in target tissues (e.g., blood, spleen and kidney) at
the beginning of treatment. Antibiotic treated animals were
sacrificed at 24 h after the last treatment dose. At sacrifice,
the target organs (e.g., blood, kidney and spleen) were removed
and quantitatively cultured. The mean lg(CFU/g) of tissue or
lg(CFU/mL) of blood (SD) was calculated for each group for
statistical comparisons.
2.11. Statistic analyses
All in vitro assays were conducted with at least two biological
replicates in triplicate. Two-tailed Student’s t-test was used to
analyze the in vitro data and S. aureus counts in the target tissues
in the murine bacteremia model between different groups. Data
were expressed as Mean (SD). P values < 0.05 were considered
significant. No adjustment was made for all the P values reported
in this study.
3. Results
3.1. MICs and FIC index
As expected, the MRSA strain JE2 was resistant to OXA, CFZ and
NAF with MICs ranging 32e256 mg/L (Table 2). The MIC of
HYP against the JE2 strain was 64 mg/L (Table 2). A synergistic
activity was observed in the combination of HYP with the study b-
lactam antibiotics against the JE2 stain with FIC index values
ranged 0.10e0.19 (Table 2). In addition, the effect of HYP in
combination with other SOC antibiotics against the study MRSA
strain was tested. Except amoxicillin, ciprofloxacin, and strepto-
mycin, all the antibiotics showed a reduction in MIC values when
used in combination with 1/8  MIC of HYP (See Supporting
Information Table S3).Table 2 MICs of HYP, OXA, NAF and CFZ, and FIC index
of the combination of HYP with the study b-lactam antibiotics
against MRSA strain JE2.
MICs (mg/L) FIC index
HYP þ b-lactam
HYP OXA CFZ NAF OXA CFZ NAF
64 256 128 32 0.10 0.19 0.19In addition, as we reported recently10, the sarA and mecA
mutants in the JE2 background had significantly decreased OXA
MICs, and the sarA mutant with plasmid mecA complemented
strain returned the OXA MIC value to near its parental JE2 level
(Table 3). In the current study, we found that the MICs of HYP on
the JE2 strain set were similar with MICs ranging 32e64 mg/L.
Importantly, addition of 1/8 MIC HYP significantly reduced the
MIC of OXA on the JE2 parental strain (decreased OXA MICsFigure 1 In vitro timeekilling curves of HYP, OXA, CFZ or NAF
alone; and the combination of HYP with OXA, CFZ or NAF against
MRSA JE2 strain. The data are the mean  SD of MRSA counts in
each group of at least two biological replicates.
Figure 2 The effect ofHYP (penal A), b-lactam alone (penal B), and the combination ofHYPwith OXA (penal C), CFZ (penalD), or NAF (penal E)
onbiofilm formation inMRSA.Control orb-lactam alone groupswere set up as 1. Relative biofilm formation levelswere represented asmean SDof at
least two biological replicates. *P < 0.05, **P < 0.01, ***P < 0.001; Penals A and B vs. control; Penal C, D and E vs. b-lactam alone.
Figure 3 The effect of HYP or OXA alone and in combination on
fibronectin binding in MRSA strain JE2. Control group was set up as
1. Relative fibronectin binding levels were represented as mean  SD
of at least two biological replicates. *P < 0.01, **P < 0.001 vs.
control; ##P < 0.001 vs. OXA alone.
1178 Genzhu Wang et al.from 256 mg/L to 8 mg/L), and showed synergistic effect with FIC
index of 0.16 (Table 3). However, this synergistic effect was not
observed on the mutant strains (Table 3; FIC index >0.5). These
data indicate that the synergistic effect of HYP with OXA might
be due to its impact on sarA, then subsequence on mecA.
3.2. Timeekilling curves
The timeekilling profiles of HYP, OXA, CFZ, and NAF alone, as
well as in combination against the MRSA strain JE2 are presented
in Fig. 1. Control cultures without antibiotic exposure increased
w4lg(CFU/mL) over the 24 h of incubation. HYP and b-lactam
antibiotics alone at sub-MIC concentrations showed minor inhi-
bition effect on the growth of the bacteria during 12 h of incu-
bation, while had similar bacterial growths vs. the control groups
at 24 h of incubation. Importantly, the combinations of HYP with
OXA, CFZ, or NAF demonstrated synergistic effect against the
MRSA strain JE2 with w2lg(CFU/mL) killing compared to their
respective most active single drug exposure during 12 h incuba-
tion. More importantly, the combinations resulted >2lg(CFU/mL)
reduction vs. HYP and b-lactams alone at 24 h time point (Fig. 1).
3.3. The effect of HYP, b-lactam antibiotics alone and in
combination on biofilm formation
HYP alone at sub-MIC levels resulted significantly less biofilm
formation than control group in a dose-dependent manner in
MRSA strain JE2 (Fig. 2A). In addition, sub-MIC of NAF had
significantly effect on the reduction of biofilm formation as
compared to the control group, while OXA and CFZ alone had
similar biofilm formation vs. the control (Fig. 2B). Of note, the
combination of HYP with the study b-lactams at sub-MIC levelssignificantly reduced biofilm formation in a dose-dependent
manner as compared to b-lactams alone (Fig. 2CeE for OXA,
CFZ and NAF, respectively), except the combination of HYP at
1/16  MIC with NAF at 1/256  MIC (Fig. 2E).
3.4. The effect of HYP, OXA alone and in combination on
fibronectin binding
As shown in Fig. 3, in the presence of sub-MICs of HYP, the
MRSA strain JE2 showed significantly decreased capability of
fibronectin binding in a dose-dependent manner vs. the control
group. Interestingly, sub-MIC of OXA exposure showed
Figure 4 The effect of HYP or OXA alone; and in combinations on sarA (Penal A), mecA (Penal B), fnbA (Penal C), agrRNAIII (Penal D) and
hla (Penal E) expressions in MRSA. Control group was set up as 1. Relative transcript levels of sarA, mecA, fnbA, agrRNAIII, and hla were
represented as mean  SD of at least two biological replicates. *P < 0.05, **P < 0.01 vs. control; #P < 0.05, ##P < 0.01 vs. OXA alone.
Figure 5 The effect of HYP on SarA binding ability to the mecA
promoter.
Synergistic effect between hypericin and b-lactams against MRSA 1179significantly increased binding to fibronectin as compared with the
control group (Fig. 3). Of importance, the combination of HYP
with OXA significantly decreased the fibronectin binding ability
of the JE2 strain vs. OXA alone exposure (Fig. 3).
3.5. The effects of HYP, OXA alone and in combination on sarA,
mecA and virulence related genes expression
It is known that mecA, encoding penicillin binding protein 2a
(PBP2a), mediates the resistance to b-lactam antibiotics in
MRSA35. In addition, we have recently demonstrated the impor-
tant role of the global regulator, sarA, in b-lactam antibiotics
resistance in MRSA10. In the current study, we found that HYP at
sub-MIC levels significantly decreased sarA and mecA expres-
sions as compared to their respective control groups (Fig. 4A and
B for sarA and mecA expression, respectively). Consistent with
our previous findings10,38, sub-MICs of OXA exposure signifi-
cantly induced sarA and mecA expressions vs. their respective
controls (Fig. 4A and B for sarA and mecA expression, respec-
tively). Interestingly, the combination of HYP and OXA signifi-
cantly reduced the expression of sarA and mecA as compared with
OXA alone (Fig. 4A and B for sarA and mecA expression,
respectively). More importantly, HYP also significantly decreased
agr RNAIII, which is a well-known sarA downstream key regu-
lator and other virulence related genes (e.g., fnbA and hla)
expression as compared to their respective control groups.
Although sub-MIC of OXA exposure significantly induced these
genes expression, the combination groups significantly reduced
these genes expression as compared with OXA alone (Fig. 4 D and
E).
3.6. The impact of HYP on the SarA-mecA binding
A direct binding of SarA to the mecA promoter fragment was
observed in a SarA protein concentration dependent manner
(Fig. 5). For instance, a nearly complete shift occurred in the
presence of 1.2 mg of SarA protein. Of importance, sub-MICs of
HYP substantially reduced the SarAemecA binding (Fig. 5).These results indicate that SarA positively controls mecA
expression through its direct binding to mecA promoter, and HYP
decreases the binding ability of SarA to mecA promoter.
3.7. The cytotoxic effect of HYP on HEK-293
The cytotoxic effect of HYP on HEK-293 cells was investigated
by using CCK-8 assay. The results showed that HEK-293 cells
were well tolerated to HYP at concentrations tested (Supporting
Information Fig. S1).
3.8. Therapeutic efficacy of HYP, OXA alone and in combination
in the murine bacteremia model
HYP monotherapy showed no significant decreased in MRSA
densities in kidney and spleen vs. the untreated controls, while
blood samples from mice treated with HYP had significantly
lower MRSA densities than those from the control animals
(Fig. 6). Treatment of OXA alone resulted significant reduced
MRSA density in all target tissues as compared with the control
groups (Fig. 6). Of great interest, the combination of HYP and
Figure 6 Therapeutic efficacy of HYP and OXA alone, and in combination in a mouse bacteremia model due to MRSA strain JE2. Each dot
represents MRSA density in target tissues in the bacteremia model in one mouse (n Z 6). Horizontal black bars indicate mean  SD MRSA
density in the target tissues. *P < 0.05; **P < 0.01; ***P < 0.001.
1180 Genzhu Wang et al.OXA exhibited significantly greater efficacy in reducing MRSA
densities in all target tissues vs. all other three groups (Fig. 6).
4. Discussion
MRSA is a major cause of invasive infections (e.g., bacteremia)
with unacceptable high morbidity and mortality since its emer-
gency in 1960s39. Vancomycin and daptomycin have been
considered as the first line of antibiotics against MRSA infections.
However, many MRSA strains have developed resistance to these
antibiotics40,41. Thus, an alternative treatment approach against
MRSA infections is urgently needed. In our previous studies, the
importance of sarA in b-lactams resistance was reported10. For
instance, we demonstrated that sarA mutant strains became more
susceptible to OXA as compared to their respective parental
MRSA strains both in vitro and in an experimental endocarditis
model. Hence, we speculated that sarA could be an optimal po-
tential target to anti-MRSA.
In the current investigation, we observed that HYP had anti-
MRSA activities with MIC of 64 mg/L. Of major importance, a
synergistic effect of HYP with b-lactams (e.g., OXA, CFZ and
NAF) was observed against MRSA strain JE2. In addition, the
combination resulted w2lg(CFU/mL) reduction during 12 h in-
cubation as compared with HYP or b-lactams alone group.
However, regrowth was observed at 24 h incubation.
It is well known that mecA plays a key role in b-lactam
resistance (e.g., OXA) in MRSA42,43. In addition, we recently
demonstrated that sarA regulates b-lactam antibiotic resistance in
MRSA both in vitro and in an experimental endocarditis model at
least in part through its effect on mecA expression10. In this study,
we observed that HYP exposure significantly decreased sarA and
mecA expression. Although OXA alone significantly induced sarA
and mecA expression, which was consistent with others previous
reported10,38,44, the addition of HYP significantly reduced sarA
and mecA expression vs. OXA alone. To further investigate
whether the synergistic effect of HYP and OXA was mediated by
sarA and/or mecA, isogenic sarA, mecA and sarA/pmecA mutant
strains in the JE2 background were used. Our results demonstrated
that there were no synergistic effects between HYP and OXA
against these mutant strains. Moreover, HYP exhibited inhibitioneffect on SarAemecA promoter binding. Taken together, these
data indicate that the synergistic effect at least in part was due to
the impact of HYP on the inhibition of sarA activity, then sub-
sequent on mecA expression.
Biofilm formation plays an important role in the pathogenesis
of staphylococci infections45. Numerous studies have demon-
strated that sarA is an important positive regulator on biofilm
formation5,46e48. The mechanism partly due to sarA negatively
regulate the activity of protease and nuclease5, while positively
control Bip49 and PIA/PNAG production50. Consistent with the
previous studies10 , we found that JE2 sarA mutant strain formed
significantly less biofilm than its isogenic parental strain. Of
importance, HYP, as a sarA inhibitor, showed significantly
reduced biofilm formation in a concentration-dependent manner in
JE2 strain. These data were consistent with other studies showing
that HYP and SarA inhibitor had anti-biofilm activity against
S. aureus strains6,15. However, the specific mechanism of HYP
against MRSA biofilm formation still need further studies.
SarA is an important transcriptional regulator that interacts
with other regulators (e.g., agr) and controls many virulence genes
(e.g., mecA, fnbA and hla) in S. aureus51,52. As reported from prior
studies, SarA binds to fnbA promoter fragments, positively regu-
lates FnBPs production and increases capacity of MRSA strains
binding to fibronectin5,53. HYP, as a sarA inhibitor, significantly
decreased fnbA expression and fibronectin binding capacity, which
were consistent with previous results related to sarA mutants and
other SarA inhibitor5,7,54. Of importance, the combination of HYP
and OXA showed significantly decreased fnbA expression and
fibronectin binding capacity vs. OXA alone. In addition, Sub-MIC
of HYP exposure significantly decreased agr RNAIII and its
downstream hla genes expression6,7, while sub-MIC of OXA
exposure significantly induced these genes expression55,56. Of
importance, the combination of HYP and OXA showed signifi-
cantly decreased these genes expression vs. OXA alone. Taken
together, our data indicate that HYP, as a sarA inhibitor, signifi-
cantly decreased agr RNAIII and its downstream virulence genes
expression.
The most important finding in the current study was that the
in vitro results were well translated into the in vivo treatment
outcomes in the murine bacteremia model due to the study MRSA
Synergistic effect between hypericin and b-lactams against MRSA 1181strain. Similar MRSA densities in kidney and spleen were
observed in the HYP monotherapy group vs. the untreated con-
trols. However, OXA treatment alone had therapeutic efficacy
with significantly reduced MRSA counts in all the target tissues as
compared with the control group. These results were in agreement
with previous studies using similar OXA treatment regimen and
bacteremia model37,38. Of important, the combination of HYP
with OXA exhibited significantly lower MRSA densities in the
target tissues vs. OXA monotherapy. These combinational thera-
peutic effects were thought to occur by inhibition of sarA, which
subsequently reduces mecA expression and OXA resistance. These
data underscored the significance of HYP, as a sarA inhibitor, in
the use with b-lactam antibiotic (e.g., OXA) for the treatment of
bacteremia due to MRSA.
5. Conclusions
We demonstrated that HYP had inhibition effect on sarA
expression, and subsequently downregulated the expression of
mecA, and increased b-lactams susceptibility in MRSA. In addi-
tion, HYP, as a sarA inhibitor, significantly reduced biofilm for-
mation, fibronectin binding and virulence-related gene expression.
Notably, combination therapy regiments of HYP and OXA
significantly enhanced in vivo efficacy of OXA in a murine
bacteremia model due to MRSA. This combinational approach
may present a novel treatment strategy against infections caused
by MRSA strains by using anti-methicillin susceptible S. aureus
(MSSA) b-lactam antibiotics.Acknowledgments
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